Filing Flows › Twist Bioscience (TWST) › Q2 FY26
Twist Bioscience (TWST) Q2 FY26 earnings results (second quarter fiscal 2026)
10-Q filed May 4, 2026
Twist Bioscience (TWST) reported revenue of $111M for the second quarter fiscal 2026 (Q2 FY26), +19% from a year earlier and +7% from the quarter before. Operating margin was -41.4%, net loss $44.0M (39.8% of revenue).
Twist Bioscience, Q2 FY26: revenue $111M (+19% year over year), operating margin -41.4%, net loss $44.0M, operating cash flow −$17.6M. The chart follows the revenue to costs, profit and cash.
| Q2 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $111M | +7% | +19% |
| Operating profit | −$45.9M | — | — |
| Net earnings | −$44.0M | — | — |
| Operating cash flow | −$17.6M | — | — |
What changed
Revenue was $110.7M in Q2 FY26, up 19% year over year and up 7% from the previous quarter. NGS applications was the largest line at 52% of revenue. DNA synthesis and protein solutions added $11.6M year over year (up 28%), 65% of the total change.
Operating costs exceeded revenue by $45.9M, an operating margin of -41.4%. Total costs grew 17% against revenue growth of 19%. The fastest-growing cost line was SG&A (+19%). The quarter ended with a net loss of $44.0M, wider than the previous quarter's $30.5M loss.
Operating cash flow was −$17.6M. Non-cash charges added back $6.4M of depreciation and amortization and $18.9M of share-based compensation. Working capital and other items added $1.1M. Capital expenditures of $7.9M exceeded it, leaving free cash flow of −$25.4M.
Questions
What was Twist Bioscience's revenue in the second quarter fiscal 2026?
Twist Bioscience (TWST) reported revenue of $111M for the second quarter fiscal 2026 (Q2 FY26), +19% from a year earlier and +7% from the quarter before.
Was Twist Bioscience profitable in the second quarter fiscal 2026?
Operating loss was $45.9M (-41.4% of revenue) and net loss $44.0M.
Source: Twist Bioscience 10-Q on SEC EDGAR.